Stifel raised the firm’s price target on OptimizeRx (OPRX) to $16 from $12.50 and keeps a Buy rating on the shares after having hosted CEO Steve Silvestro and CFO Ed Stelmakh at Stifel’s CSI Conference. Management expanded on many key themes from the Q1 earnings report, notes the analyst, who is “encouraged by many of the changes underway, including heightened focus on financial guidance/performance.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Earnings Call: Positive Growth and Strategic Shifts
- OptimizeRx price target raised to $18 from $13 at B. Riley
- OptimizeRx price target raised to $22 from $16 at Roth Capital
- OptimizeRx price target raised to $12.50 from $8 at Stifel
- OptimizeRx price target raised to $14 from $11 at Citizens JMP